These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 400529

  • 1. Iron metabolism and chelation therapy in hemosiderosis.
    Graziano JH.
    Curr Top Hematol; 1978; 1():127-50. PubMed ID: 400529
    [No Abstract] [Full Text] [Related]

  • 2. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G, Cazzavillan M, Chisesi T, Battista R, Barbui T, Dini E.
    Minerva Med; 1978 Mar 17; 69(13):811-21. PubMed ID: 643223
    [No Abstract] [Full Text] [Related]

  • 3. [Biologically active hydroxamic acids--iron complexons].
    Kol'tsova GN, Mel'nikovskaia NN, Likhodzievskiĭ KG, Rozenberg GIa.
    Gematol Transfuziol; 1984 Sep 17; 29(9):56-9. PubMed ID: 6394425
    [No Abstract] [Full Text] [Related]

  • 4. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ.
    Haematologica; 1990 Sep 17; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract] [Full Text] [Related]

  • 5. Chronic iron overload: new chelators and new strategies.
    Fairbanks VF.
    J Lab Clin Med; 1978 Aug 17; 92(2):141-3. PubMed ID: 681806
    [No Abstract] [Full Text] [Related]

  • 6. Chelation therapy for iron overload.
    Nutr Rev; 1980 May 17; 38(5):185-7. PubMed ID: 7207885
    [No Abstract] [Full Text] [Related]

  • 7. Transfusion haemosiderosis and chelation therapy.
    Ley TJ, Griffith P, Nienhuis AW.
    Clin Haematol; 1982 Jun 17; 11(2):437-64. PubMed ID: 7042160
    [No Abstract] [Full Text] [Related]

  • 8. Desferal therapy in iron storage disease.
    Thompson RB, Owen DM, Bell WN.
    Am J Med Sci; 1967 Apr 17; 253(4):453-60. PubMed ID: 6021380
    [No Abstract] [Full Text] [Related]

  • 9. [Hemochromatosis].
    Simon M, Hespel JP, Brissot P, Fauchet R, Edan G, Le Reun M, Le Mignon L, Genetet B, Bourel M.
    Ann Med Interne (Paris); 1981 Apr 17; 132(6):413-33. PubMed ID: 7032384
    [No Abstract] [Full Text] [Related]

  • 10. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan 17; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 11. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul 17; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 12. [Guidelines for diagnosis and treatment of secondary iron overload in patients with congenital anemia].
    Cario H, Grosse R, Janssen G, Jarisch A, Meerpohl J, Strauss G, German hematology societies (GPOH and DGHO).
    Klin Padiatr; 2010 Nov 17; 222(6):399-406. PubMed ID: 20862634
    [Abstract] [Full Text] [Related]

  • 13. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
    Hershko C, Grady RW, Cerami A.
    J Lab Clin Med; 1978 Aug 17; 92(2):144-51. PubMed ID: 681807
    [Abstract] [Full Text] [Related]

  • 14. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
    Corden BJ.
    Exp Hematol; 1986 Nov 17; 14(10):971-4. PubMed ID: 3770104
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B, Bunn HF, Propper RD, Nathan DG, Rosenthal DS, Moloney WC.
    Trans Assoc Am Physicians; 1977 Nov 17; 90():335-41. PubMed ID: 611665
    [No Abstract] [Full Text] [Related]

  • 16. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct 17; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 17. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
    Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA.
    J Lab Clin Med; 1993 Jul 17; 122(1):48-54. PubMed ID: 8320490
    [Abstract] [Full Text] [Related]

  • 18. Iron chelating therapy in thalassemia: current problems.
    Russo G.
    Haematologica; 1990 Jul 17; 75 Suppl 5():84-8. PubMed ID: 2086385
    [No Abstract] [Full Text] [Related]

  • 19. Iron chelation in acute iron poisoning and chronic hypersiderosis.
    Walsh JR, Gillick JB.
    Clin Pediatr (Phila); 1965 Nov 17; 4(11):633-8. PubMed ID: 5844429
    [No Abstract] [Full Text] [Related]

  • 20. [Hemosiderosis and idiopathic hemochromatosis].
    Nowotny P.
    Z Gesamte Inn Med; 1967 Dec 15; 22(24):799-806. PubMed ID: 5585476
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.